{"id":"NCT00699816","sponsor":"GC Cell Corporation","briefTitle":"Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients","officialTitle":"Randomized, Open-label, Multi-center and Phase 3 Clinical Trial to Compare the Efficacy and Safety of 'Green Cross CELL Immuncell-LC Group' and 'Non-treatment Group' in Patient Undergone Curative Resection(PEIT, RFA or Operation) for Hepatocellular Carcinoma in Korea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2012-11","completion":"2012-11","firstPosted":"2008-06-18","resultsPosted":"2015-09-24","lastUpdate":"2023-07-11"},"enrollment":230,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatocellular Carcinoma"],"interventions":[{"type":"BIOLOGICAL","name":"Immuncell-LC","otherNames":[]}],"arms":[{"label":"Immunotherapy Group","type":"EXPERIMENTAL"},{"label":"Control Group","type":"NO_INTERVENTION"}],"summary":"To prove that the efficacy and safety of 'Green Cross CELL\\* Immuncell-LC group' is superior to 'non-treatment group(Control group)' in patient undergone curative resection(PEIT, RFA or operation) for hepatocellular carcinoma in Korea","primaryOutcome":{"measure":"Recurrence Free Survival(RFS)","timeFrame":"Every 3months from the baseline for 24 months and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit)","effectByArm":[{"arm":"Immunotherapy Group","deltaMin":44,"sd":null},{"arm":"Control Group","deltaMin":30,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.01"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":14},"locations":{"siteCount":5,"countries":["South Korea"]},"refs":{"pmids":["11022927","25747273"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":115},"commonTop":["Fatigue","Pyrexia","Chills","Upper respiratory tract infection","Dyspepsia"]}}